IL-17A potentiates metastasis of hepatocellular carcinoma cells [11] and increases tumor resistance to vascular endothelial growth factor (VEGF) inhibition therapy, which makes it hard to treat certain types of cancers [12]. Here, VEGFA is linked to neoplasm.